Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Tezacaftor (VX-661) and Ivacaftor in Cystic Fibrosis
NCT01531673Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Feb 2012
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of tezacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoints: Safety as Determined by Adverse Events at Day 56 and Change in Sweat Chloride From Baseline at Day 28. Started Feb 2012; status: completed.
02
Drugs
tezacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT01531673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01531673.